Table 3 Univariate analysis of therapeutic regimens used in patients with carbapenem-resistant infections on infection-related deaths

Less than12 h onset

39 (30.7)

20 (24.1)

19 (43.2)

1.39 (1.00–1.94)

0.02

12 h onset and sensitive

31 (24.4)

14 (16.9)

17 (38.6)

1.59 (1.05–2.39)

0.006

Less than 24 h onset

53 (41.7)

30 (36.1)

23 (52.3)

1.26 (0.96–1.66)

0.059

Monotherapy

29 (22.8)

23 (27.7)

6 (13.6)

0.77 (0.60–0.98)

0.054

Combined therapy

98 (77.2)

60 (72.3)

38 (86.4)

1.29 (1.01–1.65)

0.054

 2 drugs

22 (17.3)

16 (19.3)

6 (13.6)

0.87 (0.65–1.17)

0.29

 3 drugs

53 (41.7)

31 (37.3)

22 (50.0)

1.20 (0.91–1.57)

0.11

 4 drugs

23 (18.1)

13 (15.6)

10 (22.7)

1.19 (0.81–1.74)

0.22

Colistin

107 (8.2)

67 (80.7)

40 (90.9)

1.27 (0.98–1.66)

0.10

Loading dose of colistin

74 (69.2)

43 (64.2)

31 (77.5)

1.25 (0.94–1.66)

0.10

Tigecycline

69 (54.3)

43 (51.8)

26 (59.0)

1.10 (0.86–1.42)

0.27

Double dose of tigecyclin

46 (66.8)

29 (67.5)

17 (65.4)

0.96 (0.65–1.43)

0.53

Carbapenem

69 (54.3)

42 (50.6)

27 (61.4)

1.16 (0.90–1.49)

0.16

Aminoglycoside

82 (64.6)

51 (61.4)

31 (70.4)

1.14 (0.88–1.47)

0.20

Use of more two or more drugs with in vitro activity on isolates

71 (55.9)

45 (54.2)

26 (59.0)

1.07 (0.83–1.37)

0.36